Milo Biotechnology Raises Funding from JumpStart and Rev1 Ventures

miloMilo Biotechnology, a Cleveland, Ohio-based clinical stage company developing therapies to strengthen muscle of patients with neuromuscular diseases, raised a funding round of undisclosed amount.

Backers included JumpStart’s Evergreen Fund and Rev1 Ventures’ Catalyst Fund.

The company intends to use the funds to prepare for multi-center pivotal clinical trials, which could begin in late 2017.

Founded in 2012 by CEO Al Hawkins and Brian Kaspar, Milo Biotechnology has been developing a gene-therapy program which uses a version of the protein follistatin to treat the muscle atrophy commonly associated with muscular dystrophies.
The program is based on clinical expertise that originates out of Columbus’ Nationwide Children’s Hospital.



Join the discussion